Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

6.165 +0.635 (+11.48%)
Streaming Delayed Price Updated: 10:03 AM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics Inc

< Previous 1 2 3 4 5 Next >
Analyst Expectations for Iovance Biotherapeutics's Future
 
Via Benzinga
Why Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
Gainers Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) shares rose 38.5% to $2.05 in pre-market trading after gaining 8% on Friday. 
Via Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission to U.S. Food and Drug Administration 
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Expert Ratings for Iovance Biotherapeutics
 
Via Benzinga
The Latest Analyst Ratings for Iovance Biotherapeutics
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics
 
Via Benzinga
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
First Biologics License Application (BLA) Submission on Track to Complete in 1Q23 
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
 
Via Benzinga
American Express, Visa And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
A business, clinical, and regulatory update lifted the spirits of investors. 
Via The Motley Fool
Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M
 
Via Benzinga
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today?
Although Iovance Biotherapeutics cuts a speculative figure, IOVA stock managed to skyrocket on Monday off insider buying. 
Via InvestorPlace
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday. 
Via Benzinga
Iovance Biotherapeutics Stock Is Surging: Here's Why
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher Monday following recent insider buying from Director Wayne Rothbaum. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock
Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc analyst Steve Barger maintained an Overweight rating on the stock. AMETEK shares rose 0.9% to close at $139.32 on... 
Via Benzinga
Why Iovance Biotherapeutics Is Crashing Today
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy. 
Via The Motley Fool
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
BLA Submission Ongoing with U.S. Food and Drug Administration 
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.